Based on the key indicators related to Apellis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Apellis Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Apellis Pharmaceuticals' Common Stock Total Equity is comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 149.6 M in 2026, despite the fact that Retained Earnings are likely to grow to (2.6 B).
Investors should never underestimate Apellis Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Apellis Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Apellis Pharmaceuticals.
Understanding current and past Apellis Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Apellis Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Apellis Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Check Apellis Pharmaceuticals' Beneish M Score to see the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.
Apellis Pharmaceuticals Stock Summary
Apellis Pharmaceuticals competes with Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, and Adaptive Biotechnologies. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Apellis Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Apellis Pharmaceuticals' earnings per share (EPS) will be for research and analysis purposes. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, this information can be used for research and educational purposes even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apellis Pharmaceuticals competition to find correlations between indicators driving Apellis Pharmaceuticals's intrinsic value. More Info.
Apellis Pharmaceuticals is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Apellis Pharmaceuticals is roughly 2.75 . At this time, Apellis Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Apellis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Apellis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Today, most investors in Apellis Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Apellis Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Apellis Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.34
At this time, Apellis Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Apellis Pharmaceuticals February 2, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Apellis Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Apellis Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Apellis Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Apellis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apellis Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.